The SMC approves Ilumetri (Tildrakizumab) for the treatment of psoriasis in adults in Scotland.
The Scottish Medicines Consortium (SMC) has today published its decision to recommend Ilumetri (Tildrakizumab) as a treatment for adults with moderate to severe plaque psoriasis in Scotland. This brings Scotland in line with England and Wales where the National Institute for Health and Care Excellence (NICE) approved Ilumetri for the treatment of psoriasis in April 2019.
Ilumetri may be prescribed to adult patients who have not responded to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), or who cannot tolerate these treatments.
How does Ilumetri work?
Ilumetri is a biologic treatment which blocks the activity of interleukin 23 (IL-23), a type of small protein which controls the growth of white blood cells called T cells. When these T cells become overactive, they can trigger inflammation that is linked to the development of psoriasis.
By blocking the action of IL-23, Ilumetri reduces inflammation and can therefore improve the symptoms associated with psoriasis.
How is Ilumetri taken?
Ilumetri is taken by injection at a dose of 100mg at weeks 0 and 4, and every 12 weeks thereafter.
We will be publishing more information on Ilumetri for psoriasis soon. In the meantime, please get in touch with us if you have any questions.